Abstract

Purpose: To evaluate the effectiveness of different treatment modalities for dry eye in primary Sjögren’s syndrome with their potential overlapping influences. Methods: This study included 199 patients with newly diagnosed primary Sjögren’s syndrome from 2005 to 2020. Various treatment modalities for primary Sjögren’s syndrome were compared. Improvement of corneal staining based on Sjögren’s International Collaborative Clinical Alliance (SICCA) scores was the primary outcome. Results: The average follow-up period was 5.4 ± 3.1 (range, 2.0–14.1) years. Analysis of the individual treatments showed that punctal plug insertions in the lower and upper eyelids were strongly associated with improvement of SICCA scores (β = 2.70 and 1.80, p < 0.001 and <0.001, respectively). With ocular surface inflammation, corneal staining scores improved significantly with steroid eye drops. Prednisolone (1%) had the strongest association with improvement of corneal staining scores (β = 1.48, p < 0.001); this was based on the frequency of administration. Without ocular surface inflammation, diquafosol (3%), carbomer gel, and lanolin ointment were effective (β = 1.37, 1.06, and 1.17; p = 0.003, 0.003, and <0.001, respectively). Conclusions: Punctal plug insertion, primarily targeting aqueous deficiency, is the mainstay of the treatment for dry eye in primary Sjögren’s syndrome even in the presence of ocular surface inflammation. Furthermore, the effectiveness of treatment modalities for dry eye in primary Sjögren’s syndrome was dependent on the presence of ocular surface inflammation.

Highlights

  • Sjögren’s syndrome (SS) is a long-term, progressive autoimmune disease that affects the exocrine glands, including the lacrimal and salivary glands

  • Patients with glaucoma (n = 5), patients with a follow-up period of less than two years (n = 5), patients who were enrolled in other studies (n = 3), and patients with disorders that affected eyelid function (n = 2; facial palsy and hemifacial spasm) were excluded

  • Prednisolone (1%) was the most effective steroid eye drop (β = 1.48, p < 0.001), followed by 0.5% loteprednol (β = 1.39, p = 0.012) and 0.1% fluorometholone (β = 1.25, p < 0.001)

Read more

Summary

Introduction

Sjögren’s syndrome (SS) is a long-term, progressive autoimmune disease that affects the exocrine glands, including the lacrimal and salivary glands. Its symptoms include dryness of the eyes and mouth, pain, and fatigue [1]. SS is one of the most common autoimmune diseases. Its phenotypic expression varies with geolocation and ethnicity. Its highest incidence (43 per 100,000 people) is registered in Europe and Asia [1,2,3]

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call